Phenotypes Associated with This Genotype

Genotype
MGI:4356082

• Allelic Composition: Etv6^{tm1(RUNX1)Haho}/Etv6⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S1/Sv * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

abnormal definitive hematopoiesis ( J:151639 )

• following induction with pIpC, CFU-GMs (colony forming units Granulocyte-Macrophage, myeloid) are increased and CFU-IL-7 (early B-lineage committed, lymphoid) are decreased compared to in control mice

abnormal common myeloid progenitor cell morphology ( J:151639 )

• following induction with pIpC, CFU-GEMMs (colony forming units Granulocyte, Erythroid, Macrophage, Megakaryocyte) are increased compared to in control mice

abnormal lymphopoiesis ( J:151639 )

• in repopulation assays, bone marrow cells from pIpC treated lead to reduced donor-derived lymphocyte numbers compared to when untreated cells are used

myeloid hyperplasia ( J:151639 )

• following pIpC treatment, myeloid progenitors are increased compared to in untreated mice

abnormal common lymphocyte progenitor cell morphology ( J:151639 )

• following pIpC treatment, common lymphoid progenitors and lymphoid-primed multipotential progenitor are decreased compared to in untreated mice

decreased erythroid progenitor cell number ( J:151639 )

• following induction with pIpC, BFU-Es (Burst-forming erythroid; early erythroid-committed, myeloid) are decreased compared to in controls

decreased neutrophil cell number ( J:151639 )

• mild to moderate following pIpC treatment

thrombocytopenia ( J:151639 )

• mild to moderate following pIpC treatment

decreased lymphocyte cell number ( J:151639 )

• mild to moderate following pIpC treatment

decreased B cell number ( J:151639 )

• B cells are gradually lost following pIpC treatment

increased hematopoietic stem cell number ( J:151639 )

• following pIpC treatment, the long term repopulating hematopoietic stem cells are increased 10-fold compared to in untreated mice

• in repopulation assays, bone marrow cells from pIpC treated lead to a 10-fold increase in long term repopulation hematopoietic stem cells compared to when untreated cells are used

• following pIpC treatment, the total number of cycling hematopoietic stem cells compared to in untreated mice

abnormal bone marrow cell physiology ( J:151639 )

• the proportion of quiescent (G0) hematopoietic stem cells in the bone marrow of pIpC-treated mice is increased 17-fold compared with untreated controls

• following serum and cytokine withdrawal, the hematopoietic stem cells in the bone marrow of pIpC-treated mice exhibit increased apoptosis compared with untreated controls

• following induction with pIpC, hematopoietic stem cells used in serial transplantation experiments exhaust earlier than wild-type cells

neoplasm

increased incidence of tumors by chemical induction ( J:151639 )

• following induction with pIpC and treatment with ENU, latency is shortened and a higher proportion of mice develop malignacy compared to control mice

increased leukemia incidence ( J:151639 )

• following induction with pIpC and treatment with ENU, mice develop aggressive T cell leukemias with high blast counts and replacement of normal bone marrow with CD4+ CD8+ lymphoblasts unlike in control mice

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:151639 )

• following induction with pIpC and treatment with ENU, latency is shortened and a higher proportion of mice develop malignacy compared to control mice

immune system

immune system phenotype ( J:151639 )

N • T cell development is normal following pIpC induction

abnormal lymphopoiesis ( J:151639 )

• in repopulation assays, bone marrow cells from pIpC treated lead to reduced donor-derived lymphocyte numbers compared to when untreated cells are used

myeloid hyperplasia ( J:151639 )

• following pIpC treatment, myeloid progenitors are increased compared to in untreated mice

decreased neutrophil cell number ( J:151639 )

• mild to moderate following pIpC treatment

decreased lymphocyte cell number ( J:151639 )

• mild to moderate following pIpC treatment

decreased B cell number ( J:151639 )

• B cells are gradually lost following pIpC treatment